SELLAS Life Sciences Announces Closing of $24.2 Million Public Offering
July 16, 2018 11:23 ET
|
SELLAS Life Sciences Group
NEW YORK, July 16, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...
SELLAS Life Sciences Announces Pricing of Upsized $24.2 Million Public Offering
July 12, 2018 08:45 ET
|
SELLAS Life Sciences Group
NEW YORK, July 12, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...
SELLAS Life Sciences Announces Proposed Public Offering of Common Stock
June 26, 2018 07:46 ET
|
SELLAS Life Sciences Group
NEW YORK, June 26, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or “the Company”), a clinical-stage biopharmaceutical company focused on novel cancer...
SELLAS Life Sciences Presents Interim Phase 1 Clinical Data of Galinpepimut-S (GPS) in Combination with Nivolumab to Treat Wilms Tumor 1 Positive (WT1+) Ovarian Cancer Patients at ASCO 2018
June 04, 2018 08:45 ET
|
SELLAS Life Sciences Group
1-year progression-free survival (PFS) rate of 70% with induction of serum levels of WT1 Antigen-Specific Immunoglobulin G (IgG) in 86% of patients treated with GPS in combination with programmed cell...
SELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVax™ (nelipepimut-S) Study in Combination with Trastuzumab in HER2 1+/2+ Breast Cancer Patients
June 01, 2018 08:45 ET
|
SELLAS Life Sciences Group
Phase 2b trial met key clinical objectives and is being discontinued early by the sponsor Clinical and regulatory meetings held at the American Society of Clinical Oncology (ASCO) conference Dr....
SELLAS Life Sciences to Present Phase 1/2 Clinical Data of Galinpepimut-S (GPS) in Ovarian Cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 17, 2018 08:45 ET
|
SELLAS Life Sciences Group
NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS) today announced that data from the Company’s ongoing Phase 1/2 study of galinpepimut-S (GPS) in...
SELLAS Life Sciences Receives FDA Orphan Drug Designation for Galinpepimut-S (GPS) for Treatment of Multiple Myeloma (MM)
May 09, 2018 16:30 ET
|
SELLAS Life Sciences Group
NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc. (Nasdaq:SLS) (“SELLAS”), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad...
SELLAS Life Sciences Completes Second Tranche of $10,700,000 Private Placement
May 02, 2018 08:45 ET
|
SELLAS Life Sciences Group
NEW YORK, May 02, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or “the Company”), a clinical-stage biopharmaceutical company focused on novel cancer...
SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer
April 20, 2018 08:45 ET
|
SELLAS Life Sciences Group
NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad...
SELLAS Life Sciences Reports Corporate Highlights, Advancements for its Cancer Immunotherapy Pipeline and 2017 Financial Results
April 16, 2018 09:00 ET
|
SELLAS Life Sciences Group
NEW YORK, April 16, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc. (Nasdaq:SLS) (“SELLAS”), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad...